Table Graph
   

antiviral and associated therapy - versus placebo - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.46 [0.03, 8.02]< 10%1 study (1/-)70.0 %NAnot evaluable crucial-
deaths 1.07 [0.51, 2.27]< 10%5 studies (5/-)42.5 %highnot evaluable lowcrucial-
clinical deterioration 0.75 [0.30, 1.84]< 10%2 studies (2/-)73.8 %highnot evaluable lowimportant-
clinical improvement 0.81 [0.52, 1.27]> 10%1 study (1/-)18.1 %NAnot evaluable important-
clinical improvement (7-day) 0.89 [0.77, 1.03]> 10%2 studies (2/-)6.3 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.13 [0.81, 1.56]> 146%2 studies (2/-)76.1 %highnot evaluable lowimportant-
hospital discharge 1.10 [0.90, 1.35]> 10%3 studies (3/-)83.2 %highnot evaluable lowimportant-
hospitalization 0.12 [0.01, 2.26]< 10%1 study (1/-)92.0 %NAnot evaluable important-
mechanical ventilation 0.32 [0.02, 4.80]< 10%2 studies (2/-)79.5 %some concernnot evaluable moderateimportant-
viral clearance 0.91 [0.77, 1.06]> 10%3 studies (3/-)11.1 %lownot evaluable highimportant-
viral clearance (time to event analysis only) 1.58 [0.31, 8.10]> 183%2 studies (2/-)70.6 %lownot evaluable highimportant-
viral clearance by day 14 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %NAnot evaluable important-
viral clearance by day 7 0.92 [0.78, 1.08]> 10%3 studies (3/-)15.4 %lownot evaluable highimportant-
ICU admission 1.07 [0.38, 3.00]< 10%2 studies (2/-)45.2 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.50 [0.14, 16.40]< 10%2 studies (2/-)37.1 %some concernnot evaluable moderateimportant-
adverse events 2.81 [0.70, 11.29]< 186%4 studies (4/-)7.3 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons